Instructions Cereglia soft capsules 400 mg blister No. 30
Composition
active ingredient: choline alfoscerate;
1 capsule contains choline alfoscerate 400 mg;
excipients: glycerin, purified water;
capsule shell: gelatin, liquid sorbitol, partially dehydrated, glycerin, sodium methyl parahydroxybenzoate (E 219), sodium propyl parahydroxybenzoate (E 217), titanium dioxide (E 171), iron oxide yellow (E 172).
Dosage form
Soft capsules.
Main physicochemical properties: soft gelatin capsules of oval shape, with a seam, opaque, light yellow-brown color. The contents of the capsule are a transparent colorless or slightly yellowish viscous liquid.
Pharmacotherapeutic group
Agents affecting the nervous system. Parasympathomimetics. Choline alfoscerate. ATX code N07A X02.
Pharmacological properties
Pharmacodynamics
Cereglia® is a drug belonging to the group of central cholinomimetics with a predominant effect on the central nervous system (CNS). Choline alfoscerate as a choline carrier and precursor of phosphatidylcholine has the potential to prevent and correct biochemical damage, which is of particular importance among the pathogenic factors of psychoorganic involutional syndrome, i.e. it can affect the reduced cholinergic tone and the altered phospholipid composition of nerve cell membranes.
The composition of the drug includes 40.5% of metabolically protected choline. Metabolic protection ensures the release of choline in the brain. Cereglia® has a positive effect on memory functions and cognitive abilities, as well as on indicators of emotional state and behavior, the deterioration of which was caused by the development of involutional brain pathology.
The mechanism of action is based on the fact that when choline enters the body, alfoscerate is broken down by enzymes into choline and glycerophosphate: choline takes part in the biosynthesis of acetylcholine - one of the main mediators of nervous excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane. Thus, Cereglia® improves the transmission of nerve impulses in cholinergic neurons; positively affects the plasticity of neuronal membranes and the function of receptors. Cereglia® improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in traumatic brain injury.
Pharmacokinetics
On average, almost 88% of the administered dose is absorbed. The drug accumulates mainly in the brain (45% of the drug concentration in the blood), lungs and liver. Elimination of the drug occurs mainly through the lungs in the form of carbon dioxide (CO2). Only 15% of the drug is excreted in the urine and bile.
Indication
Degenerative-involutional brain psychoorganic syndromes or secondary consequences of cerebrovascular insufficiency, i.e. primary and secondary disorders of mental activity in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased ability to concentrate; changes in the emotional and behavioral sphere: emotional instability, irritability, indifference to the environment; pseudomelancholia in the elderly.
Contraindication
Known hypersensitivity to the drug or its components. Patients with psychotic syndrome, severe psychomotor agitation. Pregnancy or breastfeeding.
Interaction with other medicinal products and other types of interactions
Clinically significant drug interactions with other drugs have not been established.
Application features
If the patient has been diagnosed with an intolerance to some sugars, contact your doctor before taking this medicinal product.
Ability to influence reaction speed when driving vehicles or other mechanisms
The drug does not affect the ability to drive vehicles and operate other mechanisms.
Use during pregnancy or breastfeeding
The drug is contraindicated for use during pregnancy or breastfeeding.
Method of administration and doses
The medicine should only be used by adults.
Take 1 capsule 2 or 3 times a day.
The duration of treatment is determined individually by the doctor.
Children
There is no experience with the use of the drug in children.
Overdose
In case of overdose with Cereglia®, which may manifest as nausea, anxiety, agitation, and insomnia, the dose of the drug should be reduced.
Therapy is symptomatic.
Adverse reactions
As a rule, the drug is well tolerated even with long-term use.
Nausea (mainly due to secondary dopaminergic activation), decreased blood pressure, headache, very rarely abdominal pain and short-term confusion may occur. In this case, the dose of the drug should be reduced.
Hypersensitivity reactions including rash, itching, urticaria, angioedema, skin redness are possible. May cause allergic reactions (possibly delayed).
Expiration date
2 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ºС.
Keep out of reach of children.
Packaging
10 capsules in a blister; 1 or 3 blisters in a pack.
Vacation category
According to the recipe.
Producer
JSC "KYIV VITAMIN FACTORY".
Location of the manufacturer and its business address
04073, Ukraine, Kyiv, Kopylivska St., 38.
